Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer with Sara Hurvitz

Antibody drug conjugates (ADC) targeting ERBB2 positive breast cancer have improved outcomes, and may even hold potential for first-line indication in some patients. Cardiomyopathy rates with conventional ERBB2 targeting therapies are well studied, however, the rate of cardiomyopathy with ADCs are less well understood. In this study investigators compared cardiomyopathy rates of ERBB2 targeting therapies including ADCs such as trastuzumab emtansine and trastuzumab deruxtican.